Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This single ascending dose (SAD) study in healthy subjects will evaluate the safety,
tolerability and pharmacokinetics of KBP-5074. PK/PD (plasma aldosterone, serum potassium and
urine albumin levels) relationships will be explored to support the selection of dosing
regimens of KBP-5074 that are suitable for the Phase 2 dose-finding study to evaluate the
efficacy, safety and tolerability of KBP-5074 in patients that could slow the progression of
nephropathy as well as control hypertension.